Brooks Laboratories (NSE:BROOKS) Cash-to-Debt : 0.44 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Brooks Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Brooks Laboratories's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.44.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Brooks Laboratories couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Brooks Laboratories's Cash-to-Debt or its related term are showing as below:

NSE:BROOKS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 44.73
Current: 0.44

During the past 13 years, Brooks Laboratories's highest Cash to Debt Ratio was 44.73. The lowest was 0.00. And the median was 0.05.

NSE:BROOKS's Cash-to-Debt is ranked worse than
62.68% of 1053 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs NSE:BROOKS: 0.44

Brooks Laboratories Cash-to-Debt Historical Data

The historical data trend for Brooks Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Brooks Laboratories Cash-to-Debt Chart

Brooks Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.01

0.03

0.10

0.44

Brooks Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															N/A	-	0.24	N/A	0.44

Competitive Comparison of Brooks Laboratories's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brooks Laboratories's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Brooks Laboratories's Cash-to-Debt falls into.

Brooks Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Brooks Laboratories's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	24.585	/	(52.854	+	3.565)
	=	0.44

Brooks Laboratories's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	24.585	/	(52.854	+	3.565)
	=	0.44

Brooks Laboratories (NSE:BROOKS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Brooks Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Brooks Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Brooks Laboratories (NSE:BROOKS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Brooks Laboratories Ltd (NSE:BROOKS) » Definitions » Cash-to-Debt

Traded in Other Exchanges

533543:India

Address

Off. Andheri Kurla Road, 201, The Summit Business Park, Behind Guru Nanak Petrol Pump, Andheri (East), Mumbai, MH, IND, 400 093

Website

https://www.brookslabs.net

Brooks Laboratories Ltd is an Indian company operating in the healthcare sector. The company is engaged in the formulation, development, production, and export of drugs and pharmaceuticals. It has manufacturing sites located in Baddi, Himachal Pradesh, and Vadodara, Gujarat. It manufactures drugs in a variety of forms, including tablets, dry syrup, injections, liquid injections, dry powder injections, eye drops, and ear drops. Its products include carbapenem and penicillins.

Brooks Laboratories (NSE:BROOKS) Headlines

No Headlines